• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Omega Therapeutics Inc.

    2/5/25 3:57:47 PM ET
    $OMGA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OMGA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001490283
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Omega Therapeutics
    SEC File Number
    001-40657
    Address of Issuer
    140 First Street
    Suite 501
    Cambridge
    MASSACHUSETTS
    02141
    Phone
    6179494360
    Name of Person for Whose Account the Securities are To Be Sold
    Richard Young
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former board member within 90 days

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services Inc
    1000 Harbor Blvd
    3rd Floor
    Weehawken � NJ � 07086
    5500001000005536621302/05/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/25/2017Founders sharesOmega TherapeuticsCheckbox not checked73911807/25/2017cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Richard Young

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OMGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMGA

    DatePrice TargetRatingAnalyst
    11/15/2024Outperform → Mkt Perform
    Raymond James
    6/18/2024$12.00Outperform
    Raymond James
    5/25/2023$18.00 → $15.00Buy
    Jefferies
    12/8/2022$11.00Buy
    H.C. Wainwright
    9/23/2022$12.00Buy
    Chardan Capital Markets
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021$30.00Buy
    Jefferies
    8/24/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $OMGA
    Financials

    Live finance-specific insights

    See more
    • Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

      All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl

      9/26/23 7:00:11 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we

      9/25/23 4:00:32 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

      First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship Pioneering Focus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences Ecosystem LONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies. The

      1/23/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

      Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target   Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced  Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev

      11/20/24 6:30:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Omega Therapeutics Inc.

      EFFECT - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/26/25 12:15:12 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Omega Therapeutics Inc.

      POS AM - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:04:35 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Omega Therapeutics Inc.

      S-8 POS - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:03:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Varsalone Jeffrey T

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      2/4/25 9:59:03 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mehrotra Ravi

      4 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:10:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Mehrotra Ravi

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:05:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/12/24 12:03:27 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 4:17:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 9:28:31 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omega Therapeutics downgraded by Raymond James

      Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform

      11/15/24 9:11:43 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Omega Therapeutics with a new price target

      Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/18/24 7:37:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Omega Therapeutics with a new price target

      Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

      5/25/23 7:51:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

      Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev

      11/14/24 4:05:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

      Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.

      11/13/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)